The first new class of pain medication in two decades

Overview

Updated May 27

For more than 20 years, doctors facing patients in severe pain had two choices: prescribe opioids that risked addiction, or use weaker alternatives that often fell short. On January 30, 2025, the Food and Drug Administration (FDA) approved suzetrigine—brand name Journavx—ending that drought as the first entirely new class of pain medication since the late 1990s.

The drug works by blocking pain signals in peripheral nerves before they reach the brain, sidestepping the neural pathways that make opioids addictive. Clinical trials showed it matched hydrocodone-acetaminophen combinations for pain relief after surgery, but without the sedation, nausea, or abuse potential. With roughly 80,000 Americans dying annually from opioid overdoses, suzetrigine offers a new option—though its $15 per tablet price and limitation to short-term use mean opioids remain widely used.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Timeline Connections

Key Indicators

20+

Years since last new pain drug class

No fundamentally new acute pain medications had been approved since COX-2 inhibitors in the late 1990s

806,000

U.S. opioid deaths (1999-2023)

Cumulative overdose deaths during the opioid epidemic

31,000x

Selectivity for pain pathways

Suzetrigine targets Nav1.8 channels with minimal effect on other tissues

$15.50

Per-tablet list price

A 14-day course exceeds $400 without insurance or assistance

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up

Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Reshma Kewalramani

Chief Executive Officer, Vertex Pharmaceuticals

Leading Vertex through pain medication expansion

Organizations Involved

Vertex Pharmaceuticals

Biotechnology Company

Developer and manufacturer of suzetrigine

Boston-based biotech that pioneered cystic fibrosis treatments and now expands into pain management and gene therapy.

U.S. Food and Drug Administration

Federal regulatory agency

Approved suzetrigine for moderate-to-severe acute pain

Federal agency responsible for approving new medications and ensuring drug safety in the United States.

Timeline

December 1995 January 2025

10 events Latest: January 30th, 2025 · 2 years ago

Tap a bar to jump to that date

January 2025
FDA Approves Suzetrigine
Latest Regulatory

FDA approved Journavx (suzetrigine) for moderate-to-severe acute pain in adults, marking the first new class of pain medication in more than two decades.
January 30th, 2025
January 2024
Phase 3 Success Announced
Clinical Trial

Vertex reported positive Phase 3 results: VX-548 significantly reduced pain versus placebo in both abdominoplasty (48.4% improvement) and bunionectomy (29.3% improvement) trials.
January 30th, 2024
January 2023
VX-548 Phase 2 Results Published
Clinical Trial

New England Journal of Medicine published Vertex's Phase 2 trial showing VX-548 provided significant pain relief compared to placebo in post-surgical patients.
January 1st, 2023
October 2017
Opioid Crisis Declared National Emergency
Government Action

President Trump declared the opioid epidemic a national public health emergency, unlocking federal resources but not additional funding.
October 26th, 2017
January 2013
Synthetic Opioid Wave Begins
Public Health

Fentanyl and other synthetic opioids began appearing in illicit drug supplies, eventually surpassing heroin and prescription opioids as the leading cause of overdose deaths.
January 1st, 2013
May 2007
Purdue Pharma Pleads Guilty
Legal

Purdue paid $600 million in fines for misleading doctors and patients about OxyContin's addiction risks—one of the largest pharmaceutical settlements at the time.
May 10th, 2007
September 2004
Vioxx Withdrawn
Safety Event

Merck voluntarily pulled rofecoxib (Vioxx) from the market after studies linked it to heart attacks and strokes, ending hopes that COX-2 inhibitors would replace opioids.
September 30th, 2004
December 1998
Celebrex Approved
Regulatory

FDA approved celecoxib, the first COX-2 inhibitor, offering pain relief with fewer stomach ulcer risks than traditional anti-inflammatories.
December 31st, 1998
January 1997
Nav1.8 Identified as Pain Target
Scientific Discovery

Researchers established that Nav1.8 sodium channels, located exclusively in peripheral pain neurons, play a critical role in transmitting pain signals.
January 1st, 1997
December 1995
OxyContin Approved
Regulatory

FDA approved Purdue Pharma's extended-release oxycodone, marketed with claims of low addiction risk that later proved false. Prescriptions for less serious pain rose tenfold over seven years.
December 1st, 1995

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

December 1995 - May 2007

OxyContin Marketing Campaign (1996-2007)

Purdue Pharma launched OxyContin in 1996 with claims that extended-release formulation made it less addictive—later proven false. Sales representatives told doctors addiction risk was "less than one percent." Prescriptions for non-cancer pain rose from 670,000 in 1997 to 6.2 million by 2002. Purdue pleaded guilty to federal charges in 2007, paying $600 million.

Then

OxyContin became the bestselling opioid in America, generating over $35 billion in total revenue for Purdue.

Now

The aggressive marketing created millions of opioid dependencies, seeding the overdose epidemic that has killed over 800,000 Americans since 1999.

Why this matters now

Suzetrigine enters a medical system still traumatized by opioid overprescription. The drug's value proposition—matching opioid-level pain relief without addiction potential—directly addresses the problem OxyContin created. But doctors burned by past promises may be skeptical of any new pain medication's claims.

December 1998 - September 2004

COX-2 Inhibitor Rise and Fall (1998-2004)

Celebrex and Vioxx launched as revolutionary pain relievers that wouldn't cause stomach ulcers like traditional anti-inflammatories. Vioxx generated $2.5 billion annually at its peak. Then came the fall: Merck withdrew Vioxx in 2004 after studies linked it to heart attacks and strokes. Bextra followed in 2005. Only Celebrex remains, carrying cardiovascular warnings.

Then

Drug withdrawals left patients with fewer non-opioid options, pushing many toward opioids for chronic pain.

Now

The FDA tightened cardiovascular safety requirements for pain medications. The failure of COX-2 inhibitors as opioid replacements contributed to continued opioid dominance for moderate-to-severe pain.

Why this matters now

Suzetrigine's peripheral mechanism—blocking pain signals before they reach the heart or brain—was designed specifically to avoid the cardiovascular risks that doomed COX-2 inhibitors. The 31,000-fold selectivity figure is meant to reassure regulators and doctors who remember Vioxx.

January 2012

Cystic Fibrosis Drug Breakthrough (2012)

Vertex's Kalydeco became the first drug to treat the underlying genetic cause of cystic fibrosis rather than just symptoms. Developed in partnership with the Cystic Fibrosis Foundation, it moved from synthesis to approval in just three years—versus the typical 15. Vertex later introduced Trikafta (2019), which helps 90% of CF patients.

Then

Patients with specific CF mutations experienced dramatic improvements in lung function and quality of life.

Now

Vertex transformed from a struggling biotech into an $80 billion company, proving that targeting root mechanisms of disease could succeed commercially.

Why this matters now

Suzetrigine represents Vertex applying the same mechanistic approach to pain: rather than dampening pain perception in the brain (like opioids), it blocks pain signals at their source in peripheral nerves. The company's CF success gives credibility to its claims of scientific innovation.